Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
20
07
2023
accepted:
18
10
2023
revised:
10
10
2023
pubmed:
8
11
2023
medline:
8
11
2023
entrez:
7
11
2023
Statut:
ppublish
Résumé
Luminal breast cancers with high proliferation (MKS Gene expression data from patients who received neoadjuvant chemotherapy (NAC) without (MDACC, N = 199) or with pembrolizumab (I-SPY2, N = 40), or endocrine therapy (NET) without (POETIC, N = 172) or with palbociclib (NeoPalAna, N = 32) were analyzed to assess treatment response by MKS/ERS-subgroups. TCGA was used to assess the mutational landscape and biomarkers associated with palbociclib-resistance (Cyclin-E, RBsig, IRPR) and immunotherapy-response (TMB, TILs, T-cell inflamed) by MKS/ERS-subgroups. Compared to MKS MKS
Sections du résumé
BACKGROUND
BACKGROUND
Luminal breast cancers with high proliferation (MKS
METHODS
METHODS
Gene expression data from patients who received neoadjuvant chemotherapy (NAC) without (MDACC, N = 199) or with pembrolizumab (I-SPY2, N = 40), or endocrine therapy (NET) without (POETIC, N = 172) or with palbociclib (NeoPalAna, N = 32) were analyzed to assess treatment response by MKS/ERS-subgroups. TCGA was used to assess the mutational landscape and biomarkers associated with palbociclib-resistance (Cyclin-E, RBsig, IRPR) and immunotherapy-response (TMB, TILs, T-cell inflamed) by MKS/ERS-subgroups.
RESULTS
RESULTS
Compared to MKS
CONCLUSIONS
CONCLUSIONS
MKS
Identifiants
pubmed: 37935787
doi: 10.1038/s41416-023-02477-7
pii: 10.1038/s41416-023-02477-7
pmc: PMC10703787
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2025-2033Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG2018 - ID21787
Informations de copyright
© 2023. The Author(s).
Références
JAMA Oncol. 2020 May 1;6(5):676-684
pubmed: 32053137
Clin Cancer Res. 2016 Jan 15;22(2):337-45
pubmed: 26423797
Clin Cancer Res. 2021 Sep 1;27(17):4870-4882
pubmed: 33536276
J Clin Oncol. 2019 May 10;37(14):1169-1178
pubmed: 30807234
J Clin Oncol. 2011 Nov 1;29(31):4160-7
pubmed: 21947828
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
JAMA Oncol. 2020 Mar 1;6(3):367-374
pubmed: 31566680
Lancet Oncol. 2023 Jan;24(1):77-90
pubmed: 36493792
Cancer Cell. 2021 Jul 12;39(7):989-998.e5
pubmed: 34143979
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
JAMA. 2011 May 11;305(18):1873-81
pubmed: 21558518
Front Oncol. 2023 Mar 06;13:1081885
pubmed: 36950554
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
BMC Cancer. 2018 Mar 24;18(1):320
pubmed: 29573739
J Natl Cancer Inst. 2020 Jul 1;112(7):737-746
pubmed: 31665365
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
J Clin Oncol. 2022 Jun 1;40(16):1816-1837
pubmed: 35439025
Clin Cancer Res. 2018 Jun 15;24(12):2804-2811
pubmed: 29559561
Lancet Oncol. 2020 Nov;21(11):1443-1454
pubmed: 33152284
Nature. 2002 Jan 31;415(6871):530-6
pubmed: 11823860
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Breast Cancer Res. 2019 Dec 31;22(1):2
pubmed: 31892336
Breast Cancer Res. 2009;11(2):R15
pubmed: 19272155
JCO Precis Oncol. 2020 Jun 26;4:
pubmed: 32923897
Breast. 2023 Jun;69:330-341
pubmed: 37003065
Clin Cancer Res. 2017 Aug 1;23(15):4055-4065
pubmed: 28270497
Clin Cancer Res. 2006 Feb 15;12(4):1157-67
pubmed: 16489069
BMC Med Genomics. 2014 Dec 03;7:64
pubmed: 25466818
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224
pubmed: 28533223
J Clin Oncol. 2010 Oct 1;28(28):4316-23
pubmed: 20805453
Breast Cancer Res. 2013;15(5):R86
pubmed: 24060333
Br J Cancer. 2018 Apr;118(8):1107-1114
pubmed: 29559730
NPJ Breast Cancer. 2022 Feb 16;8(1):19
pubmed: 35173185
J Clin Oncol. 2016 Apr 1;34(10):1134-50
pubmed: 26858339
Breast Cancer Res Treat. 2020 Sep;183(2):347-354
pubmed: 32621251
Clin Cancer Res. 2022 Jan 15;28(2):308-317
pubmed: 34667023
Clin Cancer Res. 2014 Jul 1;20(13):3569-80
pubmed: 24803582
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Cancer Res. 2010 Nov 1;70(21):8852-62
pubmed: 20959472
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
JAMA Oncol. 2017 Dec 1;3(12):1707-1711
pubmed: 28750120
Oncotarget. 2015 Jan 20;6(2):696-714
pubmed: 25557169
Nature. 2012 Jun 10;486(7403):353-60
pubmed: 22722193
Ann Oncol. 2020 Mar;31(3):387-394
pubmed: 32067680
J Clin Oncol. 2021 Aug 1;39(22):2443-2451
pubmed: 33844595
Oncotarget. 2016 Sep 13;7(42):68012-68022
pubmed: 27634906